Filing Flows › Harmony Biosciences Holdings (HRMY) › Q2 2026
Harmony Biosciences Holdings (HRMY) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 4, 2026
Harmony Biosciences Holdings (HRMY) reported revenue of $261M for the second quarter 2026 (Q2 2026), +30% from a year earlier and +21% from the quarter before. Operating margin was 34.2%, net earnings $75.4M (28.9% of revenue).
Harmony Biosciences Holdings, Q2 2026: revenue $261M (+30% year over year), operating margin 34.2%, net earnings $75.4M, operating cash flow $92.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $261M | +21% | +30% |
| Gross profit | $198M | +16% | +22% |
| Operating profit | $89.3M | +140% | +85% |
| Net earnings | $75.4M | +132% | +90% |
| Operating cash flow | $92.4M | +233% | +17% |
What changed
Revenue was $261.3M in Q2 2026, up 30% year over year and up 21% from the previous quarter.
Gross margin was 75.8%, down 5.2 points from Q2 2025. Operating profit was $89.3M, a 34.2% margin (up 10.2 points year over year). Of the extra revenue versus Q2 2025, 68% reached operating profit, above the 24% margin then. Operating expenses fell 5% while revenue rose 30%. The fastest-growing cost line was Sales & marketing (+13%). Net earnings were $75.4M, up 90% year over year. The effective tax rate was 19.1%.
Operating cash flow was $92.4M (up 17% year over year), 123% of net earnings. Non-cash charges added back $6.0M of depreciation and amortization and $9.3M of share-based compensation.
Questions
What was Harmony Biosciences Holdings' revenue in the second quarter 2026?
Harmony Biosciences Holdings (HRMY) reported revenue of $261M for the second quarter 2026 (Q2 2026), +30% from a year earlier and +21% from the quarter before.
Was Harmony Biosciences Holdings profitable in the second quarter 2026?
Operating profit was $89.3M (34.2% of revenue) and net earnings $75.4M.